Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy Launches, ...
Ultragenyx Pharmaceutical Inc (RARE) reaffirms 2026 revenue guidance of $730M--$760M, banks ~$350M in non-dilutive PRV proceeds, and trims its workforce by 20% while discontinuing two programs. Related Stocks: RARE ,